GW to get $11.6M milestone from Almirall on strong Sativex Ph III data

Spanish drugmaker Laboratorios Almirall SA will pay the UK's GW Pharmaceuticals a milestone payment of GBP8.0 million ($11.6 million)  after it obtained positive results in a recent late-stage study of their  co-developed cannabinoid drug Sativex in multiple sclerosis spasticity.  Almirall considered that the data was sufficiently positive to include  a country within its licensed territory (Europe outside the UK) as part  of the resultant Sativex regulatory submission. Following its review of  the complete data from the positive Phase III trial, Almirall has now  confirmed its positive opinion of the data and that it wishes to include  Spain in the forthcoming submission. Upon approval, Sativex will be  marketed exclusively in the UK by German drugmaker Bayer HealthCare and  in the rest of Europe by Almirall.